Kamada Said to Seek as Much as $50 Million in Nasdaq Listing

Kamada Ltd., the Israeli maker of treatments for hereditary lung diseases, hired Morgan Stanley and Jefferies Group Inc. to arrange the sale of as much as $50 million in stock in the U.S., according to a person familiar with the plans.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.